Investment Thesis — Bristol-Myers Squibb Company
The market is excessively pessimistic about Bristol-Myers Squibb's ability to navigate upcoming patent expirations, evidenced by an extreme short interest and a deeply discounted forward P/E. This undervaluation overlooks the potential of its robust late-stage pipeline and strategic capital allocation to drive future growth and earnings stability.
Catalysts
- Positive clinical trial readouts for key late-stage pipeline assets (e.g., in oncology, immunology)
- Successful integration and synergy realization from recent or future strategic M&A
- Better-than-expected sales performance of newer drugs offsetting patent cliff impacts
Risk Factors
- Failure of late-stage pipeline assets in clinical trials or regulatory approval
- More severe-than-anticipated revenue erosion from patent expirations
- Unfavorable outcomes in litigation related to existing drugs or patents
Key Debates
New drug launches reverse -3.8% revenue decline by Q4.
BMY's 9.85x Fwd P/E expands to 12x by H1 2025.
Core LOE product decline exceeds 5% by Q3 2024.